Skip to main content
Figure 2 | BMC Infectious Diseases

Figure 2

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

Figure 2

Adjusted antibody GMC ratios between the Clin and the Com groups for the 10 vaccine pneumococcal serotypes and protein D at one month post-primary vaccination (primary ATP immunogenicity cohort). Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase. Adjusted antibody GMC ratio = ratio of the geometric mean concentration at one month post-primary vaccination adjusted for country (pooled variance; Clin over Com group). PD = protein D. 95% CI = 95% confidence intervals (represented by the error bars). *Immunological non-inferiority was demonstrated if the upper limit of the 95% confidence interval of the adjusted antibody GMC ratio (Clin over Com) was below 2.0.

Back to article page